Summary & Overview
CPT 0627U: TruD MDS Schizophrenia DNA Methylation Risk Test
CPT code 0627U designates a Proprietary Laboratory Analyses (PLA) test offered only by TruDiagnostic™ Inc., marketed as TruD MDS Schizophrenia. The assay evaluates DNA methylation at more than 15,000 sites from a whole blood specimen and uses a proprietary algorithm to report a binary risk output (positive or negative) for schizophrenia. As a PLA code, 0627U identifies a single manufacturer-specific test, which has implications for billing, prior authorization, and coverage determinations nationally. Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national overview of clinical context for this molecular psychiatry test, payer coverage landscape, common billing considerations for proprietary laboratory codes, and benchmark information where available. The discussion covers service characteristics (laboratory-based, outpatient phlebotomy), reporting format (algorithmic positive/negative risk), and practical items for billing staff, including coding specificity and documentation expectations. Data not available in the input is noted where payer-specific policy details, modifiers, taxonomies, and ICD-10 linkage are required for deeper operational guidance.
Billing Code Overview
CPT code 0627U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to a single laboratory test. Report 0627U only for TruD MDS Schizophrenia from TruDiagnostic™ Inc. The test analyzes DNA methylation at more than 15,000 sites using a whole blood sample and applies an algorithm to report a positive or negative risk result for schizophrenia.
Service type: Laboratory — Proprietary molecular diagnostic test (DNA methylation analysis, whole blood sample)
Typical site of service: Clinical laboratory or independent diagnostic testing facility (blood draw performed in outpatient clinic, lab, or phlebotomy setting)
Clinical & Coding Specifications
Clinical Context
A 22-year-old patient with a family history of schizophrenia and emerging psychotic symptoms presents to an outpatient psychiatric clinic for evaluation. The treating psychiatrist orders the TruD MDS Schizophrenia test (0627U) from TruDiagnostic™ Inc. to assist in biologic risk stratification. A whole blood sample is collected in the clinic phlebotomy area or at an affiliated laboratory, labeled per laboratory instructions, and shipped to the manufacturer-specific laboratory. The laboratory performs DNA methylation analysis at more than 15,000 CpG sites and runs the proprietary algorithm to generate a binary risk report (positive or negative). The psychiatrist receives the report in the electronic health record and integrates the result with clinical assessment, history, and standardized psychiatric rating scales during follow-up visits. Billing is submitted by the performing lab or ordering provider using PLA code 0627U for the single proprietary assay.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the professional component of the laboratory service if separated billing applies (rare for PLA tests). |
TC | Technical component | Use when reporting only the technical component of the laboratory test (laboratory instrumentation, processing). |
90 | Reference (outside) lab | Use when the performing laboratory refers the specimen to another certified laboratory for the proprietary assay. |
91 | Repeat clinical diagnostic laboratory test | Use when the exact same test is repeated on the same day for confirmatory purposes per payer policy. |
59 | Distinct procedural service | Use if another distinct, separately identifiable service is provided on the same day and separate reporting is appropriate. |
26 | Professional component | Use when an independent physician provides interpretation separate from the lab (duplicate entry for emphasis of use cases). |
GQ | Telehealth originating site facility fee (other than listed) | Not typically used for lab reporting; avoid unless specific telehealth billing for consults applies per payer. |
QW | CLIA-waived test | Not applicable to this high-complexity PLA but included for payer review when CLIA status is relevant. |
ZZ | Mutually agreed upon reporting | Use if payer requires a special modifier for proprietary/PLA services (verify payer-specific guidance). |
PR | Procedure related to primary payer responsibility | Use for certain workers' compensation or liability payor situations where primary responsibility differs. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
2084P0800X | Psychiatry | Ordering and integrating results into psychiatric care plans. |
207L00000X | Clinical Laboratory | Performing laboratories that process and analyze the specimen. |
208000000X | Neurology | Consultative specialty when neuropsychiatric overlap or differential diagnosis is considered. |
363L00000X | Phlebotomy | Personnel/organizations performing blood collection for the assay. |
207K00000X | Anatomic and Clinical Pathology | Oversight and quality assurance in complex molecular testing environments. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
F20.9 | Schizophrenia, unspecified | Primary diagnostic category for which the TruD MDS Schizophrenia assay may be ordered to assess biological methylation-associated risk. |
F20.0 | Paranoid schizophrenia | Specific schizophrenia subtype where biologic risk information might be considered in the broader diagnostic workup. |
F23.0 | Acute polymorphic psychotic disorder with symptoms of schizophrenia | Acute psychotic presentations for which clinicians may seek additional biologic data to inform risk and monitoring. |
F32.9 | Major depressive disorder, single episode, unspecified | Differential diagnosis: clinicians may order biomarker testing when psychotic features or diagnostic uncertainty exist. |
R45.89 | Other symptoms and signs involving emotional state | Non-specific symptom codes used in early presentations prompting broader diagnostic testing including molecular assays. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
0627U | TruD MDS Schizophrenia (TruDiagnostic™ Inc.) — DNA methylation analysis of whole blood at >15,000 sites with algorithmic positive/negative risk result | Primary PLA code reported for the proprietary schizophrenia methylation assay. |
81002 | Urinalysis, by dipstick or tablet reagent, non-automated, without microscopy | Pre-visit screening tests sometimes performed at the same visit but not directly related to the molecular assay. |
36415 | Collection of venous blood by venipuncture | Performed to obtain the whole blood specimen required for the 0627U assay. |
88360 | Immunohistochemistry (IHC) special stain; initial single antibody stain procedure | Not typically required for this assay but listed as a molecular/diagnostic laboratory adjacent service in complex workflows. |
81479 | Unlisted molecular pathology procedure | Use when reporting other molecular tests not represented by a specific PLA or CPT; sometimes used for supplemental or confirmatory molecular analyses associated with psychiatric testing. |